Alto Neuroscience ANRO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's financing cash flow?
- Alto Neuroscience (ANRO) reported financing cash flow of $114.94M in Q1 2026.
- How has Alto Neuroscience's financing cash flow changed year-over-year?
- Alto Neuroscience's financing cash flow increased by 1159.4% year-over-year, from $9.13M to $114.94M.
- What is the long-term trend for Alto Neuroscience's financing cash flow?
- Over 2 years (2023 to 2025), Alto Neuroscience's financing cash flow has grown at a -6.1% compound annual growth rate (CAGR), from $68.18M to $60.08M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.